From neuroprogression to neuroprotection: Implications for clinical care

Medical Journal of Australia

Volumn 193, Issue 4, 2010, Pages

  Berk, Michael ^a,b,c   Conus, Philippe ^e   Kapczinski, Flávio ^f   Andreazza, Ana C ^g   Yücel, Murat ^a,d   Wood, Stephen J ^a,h   Pantelis, Christos ^a   Malhi, Gin S ^i,j,k   Dodd, Seetal ^a   Bechdolf, Andreas ^a,l   Amminger, G Paul ^d   Hickie, Ian B ^k   McGorry, Patrick D ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Geelong Clinic   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MELBOURNE HEALTH   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

^j Central Sydney Area Mental Health Service   (Australia)

^k UNIVERSITY OF SYDNEY   (Australia)

^l UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTISONE; CYTOKINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OMEGA 3 FATTY ACID; UBIDECARENONE; URIDINE; VALPROIC ACID; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; TRANQUILIZER; NEUROTROPHIN;

BIOCHEMISTRY; BIPOLAR DISORDER; COGNITION; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; LIPID PEROXIDATION; NEUROANATOMY; NEUROIMAGING; NEUROPROTECTION; OXIDATIVE STRESS; REVIEW; ARTICLE; BRAIN; COGNITIVE DEFECT; HISTOLOGY; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; BIPOLAR DEPRESSION; BIPOLAR MANIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; HEALTH CARE MANAGEMENT; NONHUMAN; TREATMENT RESPONSE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MITOCHONDRIA; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 77956996479     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Kessing LV, Andersen PK, Mortensen PB. Predictors of recurrence in affective disorder. A case register study. J Affect Disord 1998; 49: 101-108. (Pubitemid 28201999)
2. Kraepelin E. Manic depressive insanity and paranoia. Bristol: Thoemmes Press, 1921.
3. Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1-34. (Pubitemid 15231666)
4. Zis AP, Grof P, Webster M, Goodwin FK. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull 1980; 16: 47-49. (Pubitemid 10169932)
5. Berk M, Conus P, Lucas N, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007; 9: 671-678. (Pubitemid 350042401)
6. Berk M, Dodd S, Callaly P, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord 2007; 103: 181-186. (Pubitemid 47445773)
7. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230. (Pubitemid 29537524)
8. Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266.
9. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006; 188: 313-320.
10. Swann AC. The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci 2010; 1187: 276-293.
11. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry 2005; 66: 1432-1440.
12. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002; 63: 985-991.
13. Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66: 693-704. (Pubitemid 40942414)
14. Conus P, McGorry PD. First-episode mania: a neglected priority for early intervention. Aust N Z J Psychiatry 2002; 36: 158-172. (Pubitemid 34746442)
15. Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002; 159: 1841-1847.
16. Lyoo IK, Sung YH, Dager SR, et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006; 8: 65-74.
17. Garner B, Pariante CM, Wood SJ, et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005; 58: 417-423. (Pubitemid 41219710)
18. Fornito A, Malhi GS, Lagopoulos J, et al. In vivo evidence for early neurodevelopmental anomaly of the anterior cingulate cortex in bipolar disorder. Acta Psychiatr Scand 2007; 116: 467-472. (Pubitemid 350086145)
19. Hajek T, Gunde E, Bernier D, et al. Pituitary volumes in relatives of bipolar patients: high-risk study. Eur Arch Psychiatry Clin Neurosci 2008; 258: 357-362.
20. Hajek T, Gunde E, Slaney C, et al. Amygdala and hippocampal volumes in relatives of patients with bipolar disorder: a high-risk study. Can J Psychiatry 2009; 54: 726-733.
21. Hajek T, Gunde E, Slaney C, et al. Striatal volumes in affected and unaffected relatives of bipolar patients - high-risk study. J Psychiatr Res 2009; 43: 724-729.
22. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009; 113: 1-20.
23. El-Badri SM, Ashton CH, Moore PB, et al. Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disord 2001; 3: 79-87.
24. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006; 8: 103-116. (Pubitemid 44026762)
25. Lopez C, Cortez V, Palacio C, et al. Effect of chronicity on the cognitive performance of patients with bipolar disorder type I. Bipolar Disord 2008; 10 (Suppl 1): 24.
26. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.
27. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
28. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31: 858-873.
29. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32: 675-692.
30. Kato T, Kapczinski F, Berk M. Mitochondrial dysfunction and oxidative stress. In: Yatham LN, Maj M, editors. Bipolar disorder: clinical and neurobiological foundations. Hoboken, NJ: John Wiley and Sons, 2010.
31. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008; 29: 346-351.
32. Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002; 17: 175-179.
33. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-95.
34. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1355-1361.
35. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009; 23: 1079-1082.
36. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-217.
37. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447-458.
38. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 2007; 21: 1-11.
39. Baxter LR Jr, Phelps ME, Mazziotta JC, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 1985; 42: 441-447.
40. Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. Ann Med 2008; 40: 281-295.
41. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
42. Fattal O, Link J, Quinn K, et al. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007; 12: 429-438.
43. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 2001; 52: 159-164.
44. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007; 41: 523-529.
45. Kapczinski F, Frey BN, Andreazza AC, et al. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008; 30: 243-245.
46. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009; 34: 263-271.
47. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007; 421: 33-36.
48. Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215-219.
49. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11: 523-529.
50. Tramontina JF, Andreazza AC, Kauer-Sant'Anna M, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009; 452: 111-113.
51. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008; 8: 1101-1113.
52. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-876.
53. Berk M, Dodd S, Kauer-Sant'Anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007 (434): 41-49.
54. Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8: 1955-1962.
55. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.
56. Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71: 127-131.
57. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089-1093.
58. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007; 9: 743-753.
59. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
60. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-593.
61. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004; 1010: 81-86.
62. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999; 96: 8745-8750.
63. Manji HK, Lenox RH. The nature of bipolar disorder. J Clin Psychiatry 2000; 61 Supp 13: 42-57.
64. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 2006; 7: 1399-1409.
65. Berk M, Bodemer W, van Oudenhove T, Butkow N. Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. Int Clin Psychopharmacol 1994; 9: 291-293.
66. Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci 2000; 66: 2427-2432.
67. Malhi GS, Valenzuela M, Wen W, Sachdev P. Magnetic resonance spectroscopy and its applications in psychiatry. Aust N Z J Psychiatry 2002; 36: 31-43.
68. Malhi GS, Yatham LN. Mania matters! Acta Psychiatr Scand Suppl 2007; (434): 1-2.
69. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetylaspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000; 48: 1-8.
70. Forester BP, Finn CT, Berlow YA, et al. Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord 2008; 10: 691-700.
71. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242.
72. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007; 100: 279-281.
73. Berger G, Dell'Olio M, Amminger P, et al. Neuroprotection in emerging psychotic disorders [review]. Early Interv Psychiatry 2007; 1: 114-127.